• MicroRNA : still under-explored

MicroRNA are small size RNA, non coding that control gene expression at the RNA transcript level. Their mode of action implies matching with RNA target of which they are partially complementary. Such hybridization represses the translation of the corresponding protein or splits RNA. Specific microRNA are released in the blood stream and their dosage would allow to use them as biomarkers. Indeed, the modification of the expression of microRNA in certain pathologies like cancers or chronic inflammatory diseases sets them as diagnosis and prognosis biomarkers of choice. These findings have opened new tracks of development by offering wide clinical application perspectives.

• Tomorrow’s personalised medecine

Theradiag, through the acquisition of a new biotechnological platform Prestizia, strengthens its theranostic activity unit and therefore reaches another dimension of its development. This platform established at the IGMM in Montpellier (Institut de Génétique Moléculaire de Montpellier- France) is specialized in the use of microRNA to applied research in diagnostics and the monitoring of biotherapies. These molecular biomarkers, still under-explored are new tools of diagnosis and monitoring which are going to revolutionize tomorrow’s personalized medicine. The investment in this very innovative area, in parallel to the implementation of new partnerships, is going to boost this program of research and development. Among the numerous ways of possible research area, the identification of the viral tropism, and more specifically that of the HIV, is one of our first scopes.